Illumina, Inc. (ILMN) Stock Rating Upgraded by Vetr Inc.
Illumina, Inc. (NASDAQ:ILMN) was upgraded by investment analysts at Vetr from a “hold” rating to a “buy” rating in a report released on Tuesday. The brokerage presently has a $217.50 target price on the life sciences company’s stock. Vetr‘s target price points to a potential upside of 6.12% from the stock’s previous close.
A number of other research analysts also recently weighed in on the company. Argus upped their target price on Illumina from $205.00 to $235.00 and gave the stock a “buy” rating in a report on Wednesday, September 13th. Leerink Swann reiterated an “outperform” rating and set a $225.00 target price (up previously from $207.00) on shares of Illumina in a report on Tuesday, September 12th. BidaskClub downgraded Illumina from a “hold” rating to a “sell” rating in a report on Thursday, August 17th. Barclays PLC reiterated an “equal weight” rating and set a $150.00 target price on shares of Illumina in a report on Wednesday, August 9th. Finally, Canaccord Genuity upgraded Illumina from a “hold” rating to a “buy” rating and upped their target price for the stock from $170.00 to $215.00 in a report on Monday, August 7th. Three investment analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $182.15.
Shares of Illumina (NASDAQ ILMN) traded down 2.13% on Tuesday, reaching $204.95. The company’s stock had a trading volume of 1,045,834 shares. The company’s 50 day moving average price is $199.76 and its 200 day moving average price is $181.17. The company has a market cap of $29.92 billion, a P/E ratio of 41.12 and a beta of 0.81. Illumina has a 12-month low of $119.37 and a 12-month high of $214.34.
Illumina (NASDAQ:ILMN) last posted its earnings results on Tuesday, August 1st. The life sciences company reported $0.82 earnings per share for the quarter, topping analysts’ consensus estimates of $0.68 by $0.14. Illumina had a return on equity of 19.69% and a net margin of 30.27%. The firm had revenue of $662.00 million for the quarter, compared to the consensus estimate of $642.38 million. During the same quarter in the prior year, the business earned $0.86 EPS. The business’s revenue for the quarter was up 10.3% on a year-over-year basis. Analysts forecast that Illumina will post $3.65 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This report was published by American Banking News and is owned by of American Banking News. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright legislation. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/09/19/illumina-inc-ilmn-stock-rating-upgraded-by-vetr-inc.html.
In other Illumina news, SVP Charles Dadswell sold 145 shares of the stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $174.24, for a total transaction of $25,264.80. Following the completion of the transaction, the senior vice president now owns 10,646 shares of the company’s stock, valued at approximately $1,854,959.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Oene Mark Van sold 9,729 shares of the stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $211.33, for a total transaction of $2,056,029.57. Following the transaction, the senior vice president now directly owns 24,908 shares of the company’s stock, valued at approximately $5,263,807.64. The disclosure for this sale can be found here. Insiders sold a total of 195,434 shares of company stock valued at $37,480,647 in the last quarter. 1.60% of the stock is currently owned by company insiders.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Advisory Services Network LLC boosted its holdings in shares of Illumina by 13.0% during the 2nd quarter. Advisory Services Network LLC now owns 772 shares of the life sciences company’s stock valued at $134,000 after purchasing an additional 89 shares during the last quarter. Penserra Capital Management LLC boosted its holdings in shares of Illumina by 13.0% during the 2nd quarter. Penserra Capital Management LLC now owns 884 shares of the life sciences company’s stock valued at $153,000 after purchasing an additional 102 shares during the last quarter. Paradigm Asset Management Co. LLC boosted its holdings in shares of Illumina by 5.6% during the 2nd quarter. Paradigm Asset Management Co. LLC now owns 950 shares of the life sciences company’s stock valued at $165,000 after purchasing an additional 50 shares during the last quarter. Patten Group Inc. boosted its holdings in shares of Illumina by 2.7% during the 1st quarter. Patten Group Inc. now owns 965 shares of the life sciences company’s stock valued at $166,000 after purchasing an additional 25 shares during the last quarter. Finally, NN Investment Partners Holdings N.V. boosted its holdings in shares of Illumina by 11.3% during the 2nd quarter. NN Investment Partners Holdings N.V. now owns 985 shares of the life sciences company’s stock valued at $171,000 after purchasing an additional 100 shares during the last quarter. 93.32% of the stock is owned by institutional investors and hedge funds.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
To view Vetr’s full report, visit Vetr’s official website.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.